Pharmafile Logo
Pharmafocus logo
Advanced Search

Celgene

Showing 15 posts of 128 posts found.

celgene_1_02

Celgene bucks trend to strengthen neuroscience pipeline

March 21, 2018
Research and Development, Sales and Marketing Alzheimer's, Celgene, Prothena, biotech, drugs, neuroscience, pharma, pharmaceutical

Celgene has gone against industry movement to back out of the neuroscience area by putting down a potential $2.2 billion …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

March 9, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Biogen, Celgene, EMA, Gilead, HIV, Herceptin, Japan, NHS, Ontruzant, Sanofi, opioid crisis, opioids, pharma, real world data, top ten, zinbryta

After a particularly jarring bout of cold weather and snow, we may just have seen off the worst of winter …

News
celgene_1_02

Celgene strikes $101m partnership in oncology, neurodegenerative and inflammatory

March 5, 2018
Research and Development, Sales and Marketing Cancer, Celgene, Vividion, inflammatory, neurodegenerative, oncology, pharma

Celgene has inked a new multi-year partnership with biotech firm Vividion Therapeutics to leverage the latter’s proteomics and chemistry platforms …

News
top_ten

Top Ten most popular articles on Pharmafile.com this week

March 2, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Alzheimer's, AstraZeneca, Botox, Celgene, EMA, FDA, Merck, Mylan, Pfizer, Roche, Takeda, ipsen, vaccines

We’re already into March and, trying to put a bad start to the year behind them on Alzheimer’s research, the …

News
celgene_1_02

FDA refuses to review Celgene’s ozanimod in multiple sclerosis

February 28, 2018
Research and Development, Sales and Marketing Celgene, FDA, multiple sclerosis, ozanimod, pharma

Celgene has been dealt a heavy blow, revealing that the FDA has rejected its New Drug Application for its sphingosine …

News
celgene_1_02

Celgene reveals strong P3 Otezla data in rare inflammatory condition

February 19, 2018
Research and Development, Sales and Marketing Behçet's disease, Celgene, apremilast, otezla, pharma

Celgene has lifted the curtain on strong new Phase 3 data for its phosphodiesterase 4 (PDE4) inhibitor Otezla (apremilast) in …

News
stem-cell-163711_960_720

Silicon Valley-backed Celgene spin-off launches with $250m

February 16, 2018
Medical Communications, Sales and Marketing Celgene, Celularity, biotech, drugs, pharma, pharmaceutical

Biotechs are known for getting off the ground early with serious levels of financing, often based more on the acumen …

News
pharmafocus_janfeb__cover

Read Pharmafocus January/February 2018 edition online now!

January 30, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Ablynx, Alex Azr, Celgene, Pharmafocus, Sanofi, UK, artificial intelligence, bioverativ, brexit, juno therapeutics, multiple myeloma, serialisation

With the holiday period a distant memory by now, Pharmafocus is back with its January/febraury edition. It’s hard to imagine …

News
bob_hugin1

Celgene Executive Chairman Bob Hugin to retire

January 30, 2018
Manufacturing and Production, Medical Communications Bob Hugin, Celgene, pharma

Fresh from its acquisition of Juno Therapeutics, Celgene has announced that its Executive Chairman Bob Hurgin is to retire effective …

News
celgene_exteriors-3

Celgene confirms rumours, with $9bn deal for Juno

January 22, 2018
Manufacturing and Production, Sales and Marketing CAR-T, Celgene, biotech, drugs, juno therapeutics, pharma, pharmaceutical

It seems like 2018 may well be the year for M&A that everyone had expected, as two major deals on …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

January 19, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Boehringer, CAR T, CAR-T, Celgene, Kymriah, Merck KGaA, Novartis, Philippines, Sanofi, gilotrif, juno therapeutics, nestle, top ten

It’s Friday, so it’s time to bring you another run-down of the top ten most popular articles with Pharmafile.com’s readers …

News
celgene_1_02

Celgene rumoured to be revving up for Juno buyout

January 17, 2018
Research and Development, Sales and Marketing CAR-T, Celgene, Juno, biotech, drugs, pharma, pharmaceutical

Celgene has already started off the year with a bang, announcing a deal with Impact Biomedicines worth a potential $7 …

News
celgene_exteriors-3

Celgene in $7bn shot on Impact

January 8, 2018
Sales and Marketing Celgene, Impact Biomedicines, biotech, drugs, pharma, pharmaceutical

Billions of dollars do not often get put down for drugs that have been dropped by a major pharma company, …

News
celgene_exteriors-3

Cancer Research UK agrees largest drug discovery collab to date

December 15, 2017
Medical Communications, Research and Development Cancer Research UK, Celgene, biotech, drugs, pharma, pharmaceutical

Cancer Research UK has announced that its subsidiary, Cancer Research Technology (CRT), and Celgene have agreed a drug discovery collaboration. …

News
celgene_exteriors-3

Celgene hikes price of Revlimid to mask poor Q3 results

October 27, 2017
Medical Communications, Sales and Marketing Celgene, Revlimid, biotech, drugs, pharma, pharmaceutical

Celgene posted its Q3 results and investors did not react well – shares plunged 16% immediately, after the biotech cut …

News

Latest content

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023